Subcutaneous Injection
1. Type 2 Diabetes: Start with 0.25 mg/week, increasing to 0.5 mg/week after 4 weeks. For poor glycemic control, increase by 0.5 mg every 4 weeks (maximum 1 mg/week).
2. Obesity/Overweight: Start with 0.25 mg/week, increasing to 0.5 mg/week after 4 weeks, gradually increasing to 2.4 mg/week (maximum dose for weight management).
Oral Tablets
1. Type 2 Diabetes: Start with 3 mg/day, increasing to 7 mg/day after 4 weeks. For stronger control, increase to 14 mg/day (maximum dose).
Use in Special Populations
1. Pregnancy/Lactation: Contraindicated during pregnancy (may affect fetal pancreatic development); not recommended during lactation.
2. Children/Adolescents: Safety not established in patients under 18 years of age; not recommended.
3. Renal Impairment: Dose reduction is required for patients with eGFR <45 mL/min/1.73 m²; monitor renal function and gastrointestinal reactions.
4. Elderly Patients: Dose adjustment requires careful attention; close monitoring for hypoglycemia and gastrointestinal reactions is necessary.